{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:29:23Z","timestamp":1794338963761,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.therap.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:00:23Z","timestamp":1775754023000},"page":"460-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France"],"prefix":"10.1016","volume":"81","author":[{"given":"Lisa","family":"Dilange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9142-6303","authenticated-orcid":false,"given":"Karima","family":"Hider-Mlynarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Saade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jo\u00eblle","family":"Jabagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.04.001_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199200221-00003","article-title":"The quinolones. An overview of their pharmacology","volume":"22","author":"Fitton","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2026.04.001_bib0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1592\/phco.19.1.21.30507","article-title":"Trovafloxacin: an overview","volume":"19","author":"Garey","year":"1999","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"Supp. 1","key":"10.1016\/j.therap.2026.04.001_bib0215","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/clinids\/23.Supplement_1.S19","article-title":"Pharmacokinetics and pharmacodynamics of newer fluoroquinolones","volume":"23","author":"Stein","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2026.04.001_bib0220","first-page":"2741","article-title":"New classification and update on the quinolone antibiotics","volume":"61","author":"King","year":"2000","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.therap.2026.04.001_bib0225","first-page":"56","article-title":"Safety and tolerability of fluoroquinolones","volume":"45","author":"Norrby","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2026.04.001_bib0230","doi-asserted-by":"crossref","first-page":"NP121","DOI":"10.1177\/1558944717701237","article-title":"Fluoroquinolone-associated tendinopathy of the hand and wrist: a systematic review and case report","volume":"12","author":"Berger","year":"2017","journal-title":"Hand (N Y)"},{"key":"10.1016\/j.therap.2026.04.001_bib0235","first-page":"122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K1 channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.therap.2026.04.001_bib0240","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","article-title":"Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone","volume":"175","author":"Lee","year":"2025","journal-title":"JAMA Intern Med 2015"},{"key":"10.1016\/j.therap.2026.04.001_bib0245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.therap.2026.04.001_bib0250","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs. A systematic review","volume":"85","author":"Sutter","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2026.04.001_bib0255","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2026.04.001_bib0260","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2026.04.001_bib0265","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/cit439","article-title":"Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan","volume":"57","author":"Chou","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2026.04.001_bib0270","doi-asserted-by":"crossref","first-page":"ofx171","DOI":"10.1093\/ofid\/ofx171","article-title":"Risk Factors for community-associated clostridium difficile infection in adults: a case-control study","volume":"4","author":"Guh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.therap.2026.04.001_bib0275","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0000000000004247","article-title":"Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome Nested case-control study","volume":"89","author":"Sodhi","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2026.04.001_bib0280","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2012.383","article-title":"Oral fluoroquinolones and the risk of retinal detachment","volume":"307","author":"Etminan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2026.04.001_bib0285","series-title":"FDA Drug Safety Communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together","year":"2016"},{"key":"10.1016\/j.therap.2026.04.001_bib0290","unstructured":"European Medicines Agency (EMA). Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018.https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0295","unstructured":"Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise (SPILF). Diagnostic et antibioth\u00e9rapie des infections urinaires bact\u00e9riennes communautaires de l\u2019adulte \u2013 mise au point. 2015. https:\/\/www.infectiologie.com\/UserFiles\/File\/spilf\/recos\/infections-urinaires-spilf.pdf. [Accessed 31 March 2026 (43 pp.)]."},{"key":"10.1016\/j.therap.2026.04.001_bib0300","series-title":"Choix et dur\u00e9es d\u2019antibioth\u00e9rapies\u202f: cystite aigu\u00eb simple, \u00e0 risque de complication ou r\u00e9cidivante, de la femme","year":"2016"},{"key":"10.1016\/j.therap.2026.04.001_bib0305","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament (ANSM). Dossiers th\u00e9matiques - fluoroquinolones. 2022. https:\/\/ansm.sante.fr\/dossiers-thematiques\/fluoroquinolones. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0310","series-title":"Bon usage et s\u00e9curisation de l\u2019utilisation des fluoroquinolones. Syst\u00e8me d\u2019aide \u00e0 la d\u00e9cision index\u00e9e par m\u00e9dicament r\u00e9f\u00e9renc\u00e9 par la HAS","author":"Haute autorit\u00e9 de sant\u00e9 (HAS)","year":"2022"},{"key":"10.1016\/j.therap.2026.04.001_bib0315","series-title":"Mise au point sur le bon usage des fluoroquinolones administr\u00e9es par voie syst\u00e9mique chez l\u2019adulte (ciprofloxacine, l\u00e9vofloxacine, moxifloxacine, norfloxacine, ofloxacine, p\u00e9floxacine)","author":"Chidiac","year":"2015"},{"key":"10.1016\/j.therap.2026.04.001_bib0320","doi-asserted-by":"crossref","first-page":"dlaf145","DOI":"10.1093\/jacamr\/dlaf145","article-title":"Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization study","volume":"7","author":"Saade","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.therap.2026.04.001_bib0325","unstructured":"Journal officiel de la R\u00e9publique fran\u00e7aise. Arr\u00eat\u00e9 du 23 avril 2019 portant radiation de sp\u00e9cialit\u00e9s pharmaceutiques de la liste mentionn\u00e9e au premier alin\u00e9a de l\u2019article L. 162-17 du Code de la s\u00e9curit\u00e9 sociale. 2019. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000038456435. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0330","unstructured":"Journal officiel de la R\u00e9publique fran\u00e7aise. Arr\u00eat\u00e9 du 24 avril 2017 portant radiation de sp\u00e9cialit\u00e9s pharmaceutiques de la liste mentionn\u00e9e au premier alin\u00e9a de l\u2019article L. 162-17 du Code de la s\u00e9curit\u00e9 sociale. 2017. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000034519368. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0335","unstructured":"Journal officiel de la R\u00e9publique fran\u00e7aise. Arr\u00eat\u00e9 du 26 d\u00e9cembre 2017 portant radiation de sp\u00e9cialit\u00e9s pharmaceutiques de la liste des m\u00e9dicaments agr\u00e9\u00e9s \u00e0 l\u2019usage des collectivit\u00e9s publiques pr\u00e9vues \u00e0 l\u2019article L. 5123-2 du Code de la sant\u00e9 publique. 2017. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000036299544. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0340","unstructured":"Code de la Sant\u00e9 publique. Article R. 5121-152. Code de la Sant\u00e9 publique; 2013. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000028083982. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0345","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament (ANSM). Dossiers th\u00e9matiques \u2013 Bon usage du m\u00e9dicament. 2023. https:\/\/ansm.sante.fr\/dossiers-thematiques\/bon-usage-du-medicament. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0350","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.idnow.2020.12.001","article-title":"Anti-infectious treatment duration: the SPILF and GPIP French guidelines and recommendations","volume":"51","author":"Gauzit","year":"2021","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.therap.2026.04.001_bib0355","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Annex I \u2013 Definitions. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-5_en.pdf. [Accessed 31 March 2026 (32 pp.)]."},{"key":"10.1016\/j.therap.2026.04.001_bib0360","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2026.04.001_bib0365","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2026.04.001_bib0370","series-title":"Rapport sur la surveillance et la promotion du bon usage du m\u00e9dicament en France","author":"B\u00e9gaud","year":"2013"},{"key":"10.1016\/j.therap.2026.04.001_bib0375","series-title":"Rapport d\u2019expertise de pharmacovigilance relative aux fluoroquinolones [en ligne]","author":"Centre r\u00e9gional de pharmacovigilance (CRPV) Marseille","year":"2025"},{"key":"10.1016\/j.therap.2026.04.001_bib0380","unstructured":"THIN The Health Improvement Network. 2025. https:\/\/www.the-health-improvement-network.com\/. [Accessed 31 March 2026]."},{"key":"10.1016\/j.therap.2026.04.001_bib0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","article-title":"An analysis of 14 years of clinical data. 2012","volume":"12","author":"Tulkens","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.therap.2026.04.001_bib0390","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40264-023-01286-4","article-title":"Impact of European Union label changes for fluoroquinolone-containing medicinal products for systemic and inhalation use: post-referral prescribing trends","volume":"46","author":"Ly","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2026.04.001_bib0395","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/pds.4021","article-title":"Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012: off-label use of oral fluoroquinolones","volume":"25","author":"Almalki","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2026.04.001_bib0400","series-title":"Article L. 5121-12-1","year":"2023"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:18:46Z","timestamp":1794338326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0040595726000533"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.04.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}